Moderna Inc. said it asked U.S. and European health regulators Monday to authorize use of its Covid-19 vaccine, after it was shown to be 94.1% effective in a full analysis of a pivotal study.
In the 30,000-person trial, 196 subjects developed Covid-19 with symptoms after receiving either the vaccine or a placebo, Moderna said.
Of those, 185 had taken a placebo, while only 11 had gotten the vaccine, indicating it protects against the disease.
Moderna also said the vaccine appeared to be generally safe, though some subjects developed headaches and other mild to moderate reactions.
“I think this vaccine is going to be really a game changer for this pandemic,” Moderna Chief Executive Stéphane Bancel said in an interview.
Moderna, Stéphane Bancel, “, ”
Inc, U.S, Pfizer Inc, ” Moderna